The Weill Cornell Medicine (WCM) Specialized Programs of Research Excellence (SPORE) in Prostate Cancer is a key center for paradigm-shifting translational research. We aim to establish new approaches to treating PCa, which will result in improved patient outcomes and quality of life. The WCM SPORE Program endeavors to develop translational research projects with precision medicine approaches to patient care across the Prostate Cancer (PCa) Spectrum. The four SPORE projects focus on the detection and treatment of aggressive and treatment-resistant Prostate Cancer. The Developmental Research Program (DPR) will aim to attract investigators across a rich, multi-disciplinary landscape to focus on PCa translational research. The Career Enhancement Program (CEP) is committed to the development of junior faculty and future leaders in the field.
- Project 1 aims to validate a novel biomarker to monitor metastatic castration-resistant prostate cancer (CRPC) using genomic analysis of cell-free DNA (cfDNA).
- Project 2 explores targeting of N-Myc and EZH2-driven CRPC.
- Project 3 aims to develop biomarkers of disease progression and response, taking tumor heterogeneity into account by using samples from the SU2C/PCF CRPC500 clinical trial.
- Project 4 aims to characterize genomic instability observed in SPOP mutant PCa with the goal of developing treatment strategies.